---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-033087"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:48:40.724842+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics raises ~$1.615M in private placement of ADSs for working capital

## Summary
- Pricing at lower of $1.57 or 0.7× 15-day VWAP, floor $1.12 per ADS, each ADS representing 2,000 ordinary shares.
- Private placement expected to close on or about March 21, 2024, subject to customary conditions.
- Placement agent Paulson Investment to receive 10% cash fee and warrants exercisable at 125% of offering price for 5 years.
- Company agreed to file registration statement for resale of the ADSs by March 31, 2024.
- Exchange cap of 1,320,616 ADSs (19.99% of outstanding ordinary shares) unless shareholder approval obtained.

## SEC filing metadata
- accession: 0001104659-24-033087
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000110465924033087/0001104659-24-033087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000110465924033087/tm248477d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-033087
- JSON: https://secwatch.observer/filing/0001104659-24-033087.json
- Plain text: https://secwatch.observer/filing/0001104659-24-033087.txt

## Key facts
- Material Agreements
  Akari Therapeutics Plc entered into Purchase Agreement with certain existing investors valued at approximately $1,615,000 (effective 2024-03-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain existing investors
  - Value: approximately $1,615,000
  - Effective: 2024-03-11
  source text: On March 11, 2024, Akari Therapeutics, Plc (the “ Company ”) entered into a definitive agreement (the “ Purchase Agreement ”) with certain existing investors, pursuant to which the Company agreed to sell and issue in a private placement (the “ Private Placement ”) approximately $1,615,000 of unregistered American Depository Shares (“ ADSs ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000110465924033087/0001104659-24-033087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.